No data to show
OTCM
RASP
Market cap3mUSD
Jul 14, Last price
0.00USD
1D
0.00%
IPO
-99.64%
Name
Rasna Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
53.15%
Rev. gr., 5y
%
Revenues
0k
Net income
-4m
L+674.95%
CFO
-9k
L-97.28%
Profile
Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma. It focuses on developing small molecule drug candidates targeting NPM1 and LSD1, which are implicated in the disease progression of leukemia and lymphoma. The company is developing RASP-201 (LSD1), an enzyme that demethylates lysine side chain of histones; and RASP-301, an NPM1 gene that provides instructions for making nucleophosmin protein. Rasna Therapeutics, Inc. was founded in 2013 and is headquartered in New York, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑03 | 2016‑06 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 380 | 384 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (380) | (384) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | (113) | |||||||
Tax Rate | ||||||||
NOPAT | (380) | (271) | ||||||
Net income | (4,443) 674.95% | (573) -55.94% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 3,859 | |||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 211 | 128 | ||||||
Long-term debt | 92 | |||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | 136 | 180 | ||||||
| Cash flow | ||||||||
Cash from operating activities | (9) | (313) | ||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | 44 | 341 | ||||||
FCF | (104) | (873) | ||||||
| Balance | ||||||||
Cash | 75 | 39 | ||||||
Long term investments | ||||||||
Excess cash | 75 | 39 | ||||||
Stockholders' equity | (27,892) | (24,041) | ||||||
Invested Capital | 26,147 | 22,572 | ||||||
ROIC | ||||||||
ROCE | 21.76% | 26.14% | ||||||
| EV | ||||||||
Common stock shares outstanding | 578,017 | 111,426 | ||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | (380) | (384) | ||||||
EV/EBITDA | ||||||||
Interest | 213 | 941 | ||||||
Interest/NOPBT | ||||||||